NexGel Inc Common Stock (NXGL)

FairStock Score: 32/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn consistent profits, generate cash, and sell at a discount to intrinsic value. NexGel does not fit that mold yet. It makes hydrogels for wound care, diagnostics, drug delivery, and cosmetics—useful niches, but the company is tiny, with 19 employees, and the numbers show no clear durable moat. Filed results show FY2025, the year ended 2025-12-31, revenue of $11.4M and net loss of $3.0M, versus FY2024 revenue of $8.7M and net loss of $3.3M. Sales grew, but profits stayed negative. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $3.7M and net loss was $3.6M, compared with fiscal Q2 2025 revenue of $2.9M and net loss of $665,000. Revenue rose, but the loss expanded sharply. That is not healthy operating leverage.

In plain English: NexGel makes gel products used in wound care, medical tests, drug delivery, and cosmetics. The business is small and unprofitable: in the quarter ended June 30, 2026, it had $3.7 million in sales but lost $3.6 million. At its October 13, 2026 price of $4.05, the stock looks expensive compared with its weak profits and cash flow.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer